Anitua, Eduardo http://orcid.org/0000-0002-8386-5303
Murias-Freijo, Alia http://orcid.org/0009-0008-6096-1774
Tierno, Roberto
Tejero, Ricardo http://orcid.org/0000-0001-5260-5042
Alkhraisat, Mohammad Hamdan http://orcid.org/0000-0003-4422-4527
Article History
Received: 29 June 2023
Accepted: 25 July 2024
First Online: 26 August 2024
Declarations
:
: This research is part of a randomized, parallel-group, evaluators-blinded, and controlled randomized clinical trial that was designed to assess the effect of transepithelial abutment surface on the biofilm formation. The trial was registered at Trial Registration ClinicalTrials.gov under the number NCT03554876. All participants provided a written informed consent to participate. The study protocol and informed consent, in full accordance with the ethical principles of the Declaration of Helsinki of 1975, as revised in 2013, were approved by the ethical committee of investigation with medicines of the Basque Country (FIBEA-06-EC/17/Multi-Im).
: Not applicable.
: Dr. Anitua reports other from BTI Biotechnology Institute, during the conduct of the study. Other from BTI Biotechnology Institute, outside the submitted work. In addition, Dr. Anitua has a patent US8123524B2 issued to BTI Biotechnology Institute. Dr. Murias-Friejo has nothing to disclose. Dr. Tierno reports personal fees from BTI Biotechnology Institute, during the conduct of the study. Personal fees from BTI Biotechnology Institute, outside the submitted work. Dr. Tejero reports personal fees from BTI Biotechnology Institute, during the conduct of the study. Personal fees from BTI Biotechnology Institute, outside the submitted work. Dr. Alkhraisat reports personal fees from BTI Biotechnology Institute, during the conduct of the study. Personal fees from BTI Biotechnology Institute, outside the submitted work.